Osteoarthritis pain management with VIVLODEX is now available by prescription at pharmacies across the United States.

Primary tabs

Osteoarthritis pain management with VIVLODEX is now available by prescription at pharmacies across the United States.

Iroko Pharmaceuticals, LLC, a pharmaceutical company which has specilaization for analgesia has proclaimed that VIVLODEX™ (meloxicam) capsules (nonsteroidal anti-inflammatory drug) is now available at pharmacies by prescription across the United States.

In 12-week study, patients with osteoarthritis pain received VIVLODEX at low 5-mg and 10-mg doses and these capsules exhibited remarkable efficacy. Dose strenghts of VIVLODEX (5 and 10 mg) are 33% lower than oral meloxicam products which are currently available. U.S. Food and Drug Administration approved VIVLODEX for the pain management in patients with osteoarthritis.

Lou Vollmer, President and Chief Operating Officer of Iroko said "We are pleased to introduce VIVLODEX, our third low dose SoluMatrix® NSAID, and our second product for patients suffering from osteoarthritis pain". "VIVLODEX now offers patients who are currently taking oral meloxicam an effective low-dose alternative that aligns with FDA prescribing recommendations to use the lowest effective dose of NSAIDs. The launch of VIVLODEX further strengthens our commitment to provide effective low-dose NSAID options for patients experiencing pain."

Various serious adverse events of NSAID such as gastrointestinal ulcers, gastrointestinal bleeds, stroke, myocardial infarction and cardiovascular thrombotic events are reported by systematic reviews of observational studies. Such serious adverse events have evoked FDA and many professional medical organizations i.e The American College of Rheumatology, American Heart Association and American Gastroenterological Association and suggested to use NSAID at the lowest effective dose for the shortest possible duration.

"VIVLODEX demonstrated significant pain relief at low 5 mg and 10 mg doses, and may present an important new treatment option for the 27 million Americans with osteoarthritis pain," as per Dr. Clarence Young, Chief Medical Officer of Iroko Pharmaceuticals, LLC. "This latest launch provides patients living with osteoarthritis pain an efficacious, yet low dose, NSAID that aligns with recommendations by the FDA and leading professional organizations to use the lowest effective dose."



Log in or register to post comments